1. Scrip
  2. >>R&D

Parexel Execs On Obesity Drug Hurdles, Parexel GPT, India RWD Opportunity

 
• By Vibha Ravi

Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.

Parexel's Kushal Gohil, Stephen Pyke, Sanjay Vyas
L to R - Parexel’s Kushal Gohil (chief strategy officer), Sanjay Vyas (EVP and MD for India) and Stephen Pyke (EVP, Clinical Data and Digital Services) • Source: Citeline/Scrip

Eli Lilly and Company and Novo Nordisk A/S have been expanding the indications for their drugs first approved to treat obesity to add to the already huge income such products have generated.

Meanwhile, it’s not just major firms like Roche Holding AG and Pfizer Inc. playing catch up, but biotechs like Zealand Pharma A/S and Structure Therapeutics, Inc. are also developing contenders for the top prize in obesity treatment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

More from Scrip